收购继续：Agilent 2.35亿美元收购Seahorse Bio

  周三收盘后，安捷伦科技（Agilent Technologies）就与海马生物公司（Seahorse Bioscience）签订了一项最终的收购协议，协议中Agilent以2.35亿美元对Seahorse Bio进行收购。
  Seahorse位于马萨诸塞州的比勒利卡市，其可以帮助科学家们更好地理解细胞健康、功能以及信号转导等，同时也可以通过提供实时动力学来解析必要的细胞生物能学数据来帮助调查特殊药物的引入对细胞的影响。
  Seahorse公司的XF技术可以帮助研究者来调查研究细胞代谢在神经变性疾病、机体老化、癌症、心血管疾病、细胞生理学、毒理学、肝脏生物学、免疫学、感染性疾病等多种疾病中的作用及所扮演的角色。
  Agilent 生命科学及应用市场部总经理Patrick Kaltenbach在一份声明中表示，Seahorse公司独特的技术是Agilent公司市场领导地位的分离和质谱分析解决方案的一个完美补充，尤其是在代谢组学在医药研究和疾病中的研究；此次收购协议就代表着两家公司两种平台的结合，后期或将为科学家们提供更加全面深入的快速途径来帮助研究影响人类的挑战性疾病。
  这项交易预计将于今年11月1日完成，届时将实现债务融资，Seahorse公司有望在2015财年收入时获得4900万美元，同时这项交易预期也将推动Agilent在2016年的财年收入。
  目前Seahorse公司旗下有将近200名员工，大部分员工都希望加入Agilent公司，Seahorse公司位于比勒利卡市，其在位于马萨诸塞州西南部的奇科皮市拥有制造业务，而在丹麦哥本哈根和中国上海拥有其地区办事处。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的原文摘要：

Agilent Buying Seahorse Bio for $235M

Agilent Technologies and Seahorse Bioscience announced after the close of the market on Wednesday that they have signed a definitive agreement under which Agilent will acquire Seahorse for $235 million in cash. 

Seahorse is based in Billerica, Massachusetts, and its technology enables scientists to better understand cell health, function, and signaling, as well as investigate the impact of the introduction of a specific drug on the cell by providing real-time kinetics "to unlock essential cellular bioenergetics data," the firms said. 

Seahorse's XF technology is used by researchers investigating the role of cell metabolism in neurodegeneration, aging, cancer, cardiovascular disease, cell physiology, toxicology and hepatobiology, immunology, infectious diseases, mitochondrial diseases, model organisms, obesity, diabetes, and metabolic disorders, Agilent and Seahorse said. 

"Seahorse Bioscience's unique technology is the perfect complement to Agilent's market-leading separations and mass spectrometry solutions, in particular for metabolomics research and disease research in pharma," Patrick Kaltenbach, president of Agilent's Life Sciences and Applied Markets Group, said in a statement. "The combination of these two platforms gives scientists a more comprehensive and faster path to researching the most challenging diseases affecting mankind." 

The deal is expected to be completed by Nov. 1, and will be debt financed. Seahorse is expected to generate $49 million in revenues for fiscal 2015, and the deal is anticipated to be accretive to Agilent in fiscal 2016. 

Seahorse employs nearly 200 people, most of whom are expected to join Agilent. In addition to its headquarter in Billerica, the company has its manufacturing operations in Chicopee, Massachusetts and regional offices in Copenhagen, Denmark and in Shanghai.